- Home
- AUPH vs OMCL Comparison
AUPH vs OMCL Comparison
Compare AUPH & OMCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUPH | OMCL |
|---|---|---|
| Founded | 1993 | 1992 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Manufacturing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 2014 | 2000 |
Fundamental Metrics
Financial Performance| Metric | AUPH | OMCL |
|---|---|---|
| Price | $17.36 | $38.88 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $17.25 | ★ $55.83 |
| AVG Volume (30 Days) | ★ 1.1M | 607.2K |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5075.00 | N/A |
| EPS | 0.25 | 0.25 |
| Revenue | $283,055,000.00 | ★ $787,309,000.00 |
| Revenue This Year | $17.54 | $6.77 |
| Revenue Next Year | $15.74 | $5.22 |
| P/E Ratio | ★ $65.84 | $156.20 |
| Revenue Growth | ★ 20.38 | 9.93 |
| 52 Week Low | $7.29 | $26.85 |
| 52 Week High | $16.88 | $51.84 |
Technical Indicators
Market Signals| Indicator | AUPH | OMCL |
|---|---|---|
| Relative Strength Index (RSI) | 68.37 | 42.40 |
| Support Level | $14.60 | $35.81 |
| Resistance Level | N/A | $45.06 |
| Average True Range (ATR) | 0.57 | 1.71 |
| MACD | 0.13 | -0.37 |
| Stochastic Oscillator | 65.64 | 31.89 |
Price Performance
Historical ComparisonAbout AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.